CTKB icon

Cytek Biosciences

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 83.3%
Negative

Neutral
GlobeNewsWire
1 month ago
Cytek® Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional Impact
Cytek Biosciences celebrates one year of operations at its Singapore facility, which has enhanced Cytek's manufacturing capacity and regional service.
Cytek® Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional Impact
Negative
Zacks Investment Research
1 month ago
Cytek Biosciences, Inc. (CTKB) Reports Q4 Loss, Tops Revenue Estimates
Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of $0.02. This compares to earnings of $0.07 per share a year ago.
Cytek Biosciences, Inc. (CTKB) Reports Q4 Loss, Tops Revenue Estimates
Neutral
Seeking Alpha
1 month ago
Cytek Biosciences, Inc. (CTKB) Q4 2025 Earnings Call Transcript
Cytek Biosciences, Inc. (CTKB) Q4 2025 Earnings Call Transcript
Cytek Biosciences, Inc. (CTKB) Q4 2025 Earnings Call Transcript
Neutral
GlobeNewsWire
1 month ago
Cytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results  and Provides 2026 Outlook
FREMONT, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2025.
Cytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results  and Provides 2026 Outlook
Neutral
GlobeNewsWire
1 month ago
Cytek Biosciences to participate at the TD Cowen 46th Annual Health Care Conference
FREMONT, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA.
Cytek Biosciences to participate at the TD Cowen 46th Annual Health Care Conference
Neutral
GlobeNewsWire
2 months ago
Cytek Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
FREMONT, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the fourth quarter and full year 2025 after market close on Thursday, February 26, 2026.
Cytek Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Neutral
Seeking Alpha
3 months ago
Cytek Biosciences, Inc. (CTKB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Cytek Biosciences, Inc. (CTKB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Cytek Biosciences, Inc. (CTKB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral
GlobeNewsWire
3 months ago
Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results
Company to present at the 44th Annual JP Morgan Healthcare Conference Company to present at the 44th Annual JP Morgan Healthcare Conference
Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results
Negative
Seeking Alpha
4 months ago
Cytek Biosciences Is A Speculative Buy On Recurring Revenue Growth
Cytek Biosciences offers a full-spectrum cytometry platform. This means they provide instruments, reagents, services, and cloud software. Their main value proposition is to allow clients to achieve higher-parameter cell analysis than conventional flow systems. Its core product portfolio centers around Aurora, Northern Lights, Aurora CS, and Aurora Evo. Each targets a different price-performance tier.
Cytek Biosciences Is A Speculative Buy On Recurring Revenue Growth
Neutral
GlobeNewsWire
5 months ago
TIME Recognizes Cytek® Biosciences as One of America's Growth Leaders of 2026
FREMONT, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced its inclusion on TIME's 2026 list of America's Growth Leaders.
TIME Recognizes Cytek® Biosciences as One of America's Growth Leaders of 2026